Company research
REPLIGEN CORP
CIK 730272Updated Sep 24, 2026
SecurityRGEN · NASDAQ · equity
RGEN price & chart
Loading TradingView…
NASDAQ:RGEN on TradingView ↗About the company
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the Company see our website at www.repligen.com, and follow us on LinkedIn.
In the news
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance ↗
Recent filings
4 filing
144 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
425 filing
Other Events
Items 8.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,949,699,000Source | 2,829,666,000Source | 2,831,185,000Source | 2,524,658,000Source |
| Property, Plant and Equipment, NetUSD | 186,614,000Source | 197,738,000Source | 207,440,000Source | 190,673,000Source |
| GoodwillUSD | 1,114,408,000Source | 1,030,995,000Source | 987,120,000Source | 855,513,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 386,147,000Source | 397,897,000Source | 406,957,000Source | 353,676,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 566,021,000Source | 757,355,000Source | 751,323,000Source | 523,458,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 158,587,000Source | 134,115,000Source | 124,161,000Source | 116,247,000Source |
| Inventory, NetUSD | 170,458,000Source | 142,964,000Source | 202,321,000Source | 238,277,000Source |
| Assets, CurrentUSD | 1,137,385,000Source | 1,066,041,000Source | 1,111,346,000Source | 998,118,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 40,712,000Source | 31,607,000Source | 33,541,000Source | 19,837,000Source |
| Operating Lease, Right-of-Use AssetUSD | 119,538,000Source | 135,378,000Source | 115,515,000Source | 125,023,000Source |
| Other Assets, NoncurrentUSD | 4,913,000Source | 868,000Source | 1,277,000Source | 815,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 843,570,000Source | 856,948,000Source | 866,340,000Source | 613,958,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 563,000Source | 561,000Source | 558,000Source | 556,000Source |
| Retained Earnings (Accumulated Deficit)USD | 456,248,000Source | 407,354,000Source | 432,868,000Source | 397,272,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,531,000Source | -52,533,000Source | -37,808,000Source | -34,394,000Source |
| Stockholders' Equity Attributable to ParentUSD | 2,106,129,000Source | 1,972,718,000Source | 1,964,845,000Source | 1,910,700,000Source |
| Additional Paid in Capital, Common StockUSD | 1,651,849,000Source | 1,617,336,000Source | 1,569,227,000Source | 1,547,266,000Source |
| Liabilities and EquityUSD | 2,949,699,000Source | 2,829,666,000Source | 2,831,185,000Source | 2,524,658,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 135,826,000Source | 126,787,000Source | 164,942,000Source | 404,196,000Source |
| Operating Lease, Liability, CurrentUSD | 21,559,000Source | 15,104,000Source | 5,631,000Source | 6,957,000Source |
| Accounts Payable, CurrentUSD | 30,010,000Source | 32,134,000Source | 19,563,000Source | 27,554,000Source |
| Operating Lease, Liability, NoncurrentUSD | 126,176,000Source | 145,576,000Source | 126,578,000Source | 131,389,000Source |
| Other Liabilities, NoncurrentUSD | 15,555,000Source | 16,581,000Source | 11,283,000Source | 3,814,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 79,208,000Source | 62,423,000Source | 57,313,000Source | 71,120,000Source |
| Deferred Revenue, CurrentUSD | 14,609,000Source | 13,243,000Source | 17,067,000Source | 19,283,000Source |
| Deferred Tax Liabilities, NetUSD | 21,802,000Source | 22,026,000Source | 37,794,000Source | 22,160,000Source |
| Long-term DebtUSD | 542,213,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 32,605,000Source | 48,070,000Source | 25,575,000Source | 27,316,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 17,165,000Source | 14,031,000Source | 3,312,000Source | 3,596,000Source |
| Increase (Decrease) in InventoriesUSD | 14,947,000Source | -56,895,000Source | -40,973,000Source | 57,204,000Source |
| Increase (Decrease) in Accounts PayableUSD | -4,150,000Source | 12,898,000Source | -9,803,000Source | -8,197,000Source |
| Deferred Income Tax Expense (Benefit)USD | -3,373,000Source | -16,790,000Source | 1,175,000Source | -1,352,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 117,417,000Source | 175,394,000Source | 113,918,000Source | 172,083,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 70,328,000Source | 54,765,000Source | 186,642,000Source | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -298,474,000Source | -86,383,000Source | -123,275,000Source | -233,236,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | 2,397,000Source | -1,287,000Source | -32,000Source | -110,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 23,519,000Source | 25,677,000Source | 36,222,000Source | 84,834,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 8,833,000Source | 9,882,000Source | 13,227,000Source | 17,018,000Source |
| Payments for Repurchase of Common StockUSD | 0Source | 0Source | 14,386,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -15,205,000Source | -82,902,000Source | 248,961,000Source | -13,337,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | 0Source | 0Source | -45,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -191,334,000Source | 6,032,000Source | 227,865,000Source | -80,356,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 566,021,000Source | 757,355,000Source | 751,323,000Source | 523,458,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 6,070,000Source | 988,000Source | 1,033,000Source |
| Income Taxes Paid, NetUSD | 20,925,000Source | 19,298,000Source | 26,963,000Source | 34,365,000Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | 1,660,000Source | — | — | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | 16,646,000Source | — | — | — |
| Amortization of Intangible AssetsUSD | 39,100,000Source | 34,700,000Source | 31,600,000Source | 27,100,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | 0Source | — | — | — |
| DepreciationUSD | 39,700,000Source | 35,000,000Source | 37,000,000Source | 23,900,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 13,014,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | -3,596,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | 0Source | -12,676,000Source | — |
| GoodwillUSD | 1,114,408,000Source | 1,030,995,000Source | 987,120,000Source | 855,513,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 13,489,000Source | -1,521,000Source | 21,111,000Source | 33,181,000Source |
| InterestExpenseNonoperatingUSD | 21,513,000Source | 20,731,000Source | 2,503,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | 48,894,000Source | -25,514,000Source | 35,596,000Source | 185,959,000Source |
| Nonoperating Income (Expense)USD | 7,216,000Source | 8,079,000Source | 9,004,000Source | -5,530,000Source |
| Other Nonoperating Income (Expense)USD | 2,815,000Source | -5,174,000Source | 8,123,000Source | -9,531,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 0Source | 0Source | 102,323,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 3,176,000Source | 4,294,000Source | 1,076,000Source | 3,707,000Source |
| Restructuring CostsUSD | 4,135,000Source | 46,935,000Source | 32,200,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 738,256,000Source | 634,439,000Source | 632,362,000Source | 801,536,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of RevenueUSD | 352,011,000Source | 359,794,000Source | 353,922,000Source | 345,830,000Source |
| Selling, General and Administrative ExpenseUSD | 290,508,000Source | 263,368,000Source | 218,584,000Source | 215,829,000Source |
| Operating Income (Loss)USD | 55,167,000Source | -35,114,000Source | 47,703,000Source | 224,670,000Source |
| Other Nonoperating Income (Expense)USD | 2,815,000Source | -5,174,000Source | 8,123,000Source | -9,531,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 62,383,000Source | -27,035,000Source | 56,707,000Source | 219,140,000Source |
| Income Tax Expense (Benefit)USD | 13,489,000Source | -1,521,000Source | 21,111,000Source | 33,181,000Source |
| Net Income (Loss) Attributable to ParentUSD | 48,894,000Source | -25,514,000Source | 35,596,000Source | 185,959,000Source |
| Earnings Per Share, BasicUSD per share | 0.87Source | -0.46Source | 0.64Source | 3.35Source |
| Earnings Per Share, DilutedUSD per share | 0.86Source | -0.46Source | 0.63Source | 3.24Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 56,234Source | 55,937Source | 55,720Source | 55,460Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 56,561Source | 55,937Source | 56,377Source | 57,455Source |
| Interest Expense (non-operating)USD | 21,513,000Source | 20,731,000Source | 2,503,000Source | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 39,100,000Source | 34,700,000Source | 31,600,000Source | 27,100,000Source |
| Costs and ExpensesUSD | 683,089,000Source | 669,553,000Source | 584,659,000Source | 576,866,000Source |
| Current Income Tax Expense (Benefit)USD | 16,862,000Source | 15,037,000Source | 19,941,000Source | 34,800,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 78,745,000Source | 69,673,000Source | 68,556,000Source | 50,985,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 13,014,000Source | — | — | — |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -23,511,000Source | -89,321,000Source | -24,888,000Source | 153,446,000Source |
| Interest ExpenseUSD | — | — | 1,951,000Source | 1,162,000Source |
| Interest Expense, DebtUSD | 22,646,000Source | — | — | — |
| Investment Income, NetUSD | 27,574,000Source | 35,827,000Source | 24,135,000Source | 6,978,000Source |
| Nonoperating Income (Expense)USD | 7,216,000Source | 8,079,000Source | 9,004,000Source | -5,530,000Source |
| Research and Development ExpenseUSD | 54,177,000Source | 43,200,000Source | 42,722,000Source | 43,936,000Source |
| Restructuring CostsUSD | 4,135,000Source | 46,935,000Source | 32,200,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 738,256,000Source | 634,439,000Source | 632,362,000Source | 801,536,000Source |
Offerings
Registration 333-298546
Filing attachments
d127719dex991.htm · S-4 · 2026-08-25
EX-99.1 5 d127719dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Board of Directors BioLife Solutions, Inc. 3303 Monte Villa Parkway, Suite 310 Bothell, WA 98021 The Board of Directors: We hereby consent to the inclusion of our opinion letter, dated July 21, 2026, to the Board of Directors of BioLife Solutions, Inc. as Annex B to, and reference to such opinion letter under the headings “Summary,” “The Mergers - Background of the Mergers,” “The Mergers - Recommendation of the BioLife Board of …
Read attachment ↗d127719dex992.htm · S-4 · 2026-08-25
EX-99.2 6 d127719dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Preliminary - Subject to Completion SCAN TO VIEW MATERIALS & VOTE w BIOLIFE SOLUTIONS, INC. VOTE BY INTERNET C/O BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC. Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above P.O. BOX 1342 BRENTWOOD, NY 11717 Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on [TBD], 2026. Have your proxy card in ha…
Read attachment ↗rgen-ex99_1.htm · 8-K · 2026-07-28
EX-99.1 2 rgen-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance • Second quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organic • GAAP operating income increased 1% year-over-year while adjusted operating income increased 55% • Raising both FY26 organic re…
Read attachment ↗d141685dex991.htm · 8-K · 2026-07-22
EX-99.1 3 d141685dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media Fast-tracks Repligen’s leadership and customer solution offering in high-growth cell therapy market by adding BioLife’s differentiated, high-margin recurring revenue business BioLife stockholders to receive cash and Repligen common stock at a value of $31.00 per share, representing a total enterprise value of app…
Read attachment ↗d141685dex992.htm · 8-K · 2026-07-22
EX-99.2 4 d141685dex992.htm EX-99.2 EX-99.2 July 22, 2026 Repligen to Acquire BioLife Solutions Exhibit 99.2 Safe Harbor Statement Cautionary Statement Regarding Forward-Looking Statements Statements included in this presentation, which are not historical in nature or do not relate to current facts, are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provisions of the federal securities laws, including Section 27A of the Securities A…
Read attachment ↗rgen-ex99_1.htm · 8-K · 2026-05-05
EX-99.1 2 rgen-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance • First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organic • GAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-year • Reiterating FY26 organic revenue growth gu…
Read attachment ↗